Dose EScalation Induction of EvERolimus

Clinical trial NCT02387099 · COMPLETED

Trial details

NCT number: NCT02387099
Sponsor: GBG Forschungs GmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Hormone Receptor Positive Tumor

Start date: 2015-05-01
Primary completion: 2021-05-01
Enrollment: 156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.